4
2
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T69882 |
Pefabloc
|
Others | Others |
Pefabloc is an irreversible serine proteinase inhibitor. Pefabloc efficiently inhibits both human and rat platelet activating factor (PAF)-degrading acetylhydrolase (acetylhydrolase). | |||
T63344 |
Lp-PLA2-IN-4
|
Others | Others |
Lp-PLA2-IN-4 是有效的脂蛋白相关磷脂酶 A2 (Lp-PLA2) 抑制剂。其中 Lp-PLA2 曾经被称作血小板活化因子乙酰水解酶 (PAF-AH),是参与脂蛋白脂质或磷脂水解的磷脂酶 A2。Lp-PLA2-IN-4 具有潜力进行 Lp-PLA2 活性相关的疾病的研究,如阿尔茨海默病 、动脉粥样硬化。 | |||
T63345 |
Lp-PLA2-IN-5
|
Others | Others |
Lp-PLA2-IN-5 是有效的脂蛋白相关磷脂酶 A2 (Lp-PLA2) 抑制剂。其中 Lp-PLA2 曾经被称作血小板活化因子乙酰水解酶 (PAF-AH),是参与脂蛋白脂质或磷脂水解的磷脂酶 A2。Lp-PLA2-IN-5 具有潜力进行 Lp-PLA2 活性相关的疾病的研究,如阿尔茨海默病 、动脉粥样硬化。 | |||
T63192 |
Lp-PLA2-IN-10
|
Others | Others |
Lp-PLA2-IN-10 是一种有效的脂蛋白相关磷脂酶 A2 (Lp-PLA2) 抑制剂。Lp-PLA2-IN-10 能够用于神经退行性相关疾病的研究,如阿尔茨海默病(AD)、青光眼、年龄相关的黄斑变性 (AMD),或者包括动脉粥样硬化等心血管疾病。Lp-PLA2 曾经被称作血小板活化因子乙酰水解酶 (PAF-AH),是一种参与脂蛋白脂质或磷脂水解的磷脂酶 A2。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPJ-01054 |
PAFAHB Protein, Human, Recombinant (His)
PAFAH Subunit Beta,PAF-AH 30 kDa Subunit,Platelet-<... |
Human | E. coli |
Platelet-Activating Factor Acetylhydrolase IB Subunit β (PAFAHB) is a cytoplasmic hydrolase. PAFAHB is a member of the GDSL lipolytic enzyme family. It also belongs to Platelet-activating factor acetylhydrolase IB beta/gamma subunits subfamily. Cytosolic PAF-AH IB is formed of three subunits of 45 kDa (alpha), 30 kDa (beta) and 29 kDa (gamma), PAFAHB is a catalytic subunit. PAFAHB inactivates PAF by removing the acetyl group at the sn-2 position. | |||
TMPJ-00553 |
Lp-PLA2/PLA2G7 Protein, Human, Recombinant (aa 22-441, His)
PAF Acetylhydrolase,LDL-Associated Phospholipase A2... |
Human | HEK293 Cells |
Platelet-Activating Factor Acetylhydrolase (PAFAH) is a secreted enzyme which belongs to the AB hydrolase superfamily and Lipase family and catalyzes the degradation of platelet-activating factor to biologically inactive products. PAFAH is produced by inflammatory cells and hydrolyzes oxidised phospholipids in LDL. PAFAH has been implicated in the development of atherosclerosis and has also been identified as a marker for cardiac disease. PAFAH might have a major physiologic effect in the presen... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T70882 |
Orlistat-d3
|
||
Orlistat-d3 is intended for use as an internal standard for the quantification of orlistat by GC- or LC-MS. Orlistat is a digestive lipase inhibitor. It inhibits diacylglycerol lipase α (DAGLα), DAGLβ, α/β-hydrolase domain-containing protein 12 (ABHD12), ABHD16A, and platelet-activating factor acetylhydrolase (PAF-AH; IC50s = 0.06, 0.1, 0.08, 0.03, and 0.05 µM, respectively), as well as pancreatic lipase and hormone-sensitive lipase (IC50s = 0.65 and 2.1 µg/ml, respectively) but does not inhibit... |